874 related articles for article (PubMed ID: 16166452)
1. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
[TBL] [Abstract][Full Text] [Related]
2. Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.
Zhu XJ; Yang ZF; Zhou JY; Liu L; Sun XM; Fan ZF; Hu SY; Chen YC; Li WX; Cao M; Wang LX
PLoS One; 2015; 10(7):e0132799. PubMed ID: 26181041
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.
Fridlender ZG; Sun J; Singhal S; Kapoor V; Cheng G; Suzuki E; Albelda SM
Mol Ther; 2010 Nov; 18(11):1947-59. PubMed ID: 20683443
[TBL] [Abstract][Full Text] [Related]
4. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S
Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234
[TBL] [Abstract][Full Text] [Related]
5. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL
Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209
[TBL] [Abstract][Full Text] [Related]
6. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
Ko HJ; Kim YJ; Kim YS; Chang WS; Ko SY; Chang SY; Sakaguchi S; Kang CY
Cancer Res; 2007 Aug; 67(15):7477-86. PubMed ID: 17671218
[TBL] [Abstract][Full Text] [Related]
7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
8. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
Vincent J; Mignot G; Chalmin F; Ladoire S; Bruchard M; Chevriaux A; Martin F; Apetoh L; Rébé C; Ghiringhelli F
Cancer Res; 2010 Apr; 70(8):3052-61. PubMed ID: 20388795
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Tumor Control of HER2 DNA Vaccines Is Achieved by an Alteration of Tumor Cells and Tumor Microenvironment by Gemcitabine and Anti-Gr-1 Ab Treatment in a HER2-Expressing Tumor Model.
Danishmalik SN; Sin JI
DNA Cell Biol; 2017 Sep; 36(9):801-811. PubMed ID: 28777668
[TBL] [Abstract][Full Text] [Related]
10. Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.
Zhang J; Zhou Z; Wang C; Shen J; Zheng Y; Zhang L; Wang J; Xia D
Cancer Immunol Immunother; 2011 Apr; 60(4):559-73. PubMed ID: 21240488
[TBL] [Abstract][Full Text] [Related]
11. Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions.
Spallanzani RG; Dalotto-Moreno T; Raffo Iraolagoitia XL; Ziblat A; Domaica CI; Avila DE; Rossi LE; Fuertes MB; Battistone MA; Rabinovich GA; Salatino M; Zwirner NW
Cancer Immunol Immunother; 2013 Dec; 62(12):1781-95. PubMed ID: 24114144
[TBL] [Abstract][Full Text] [Related]
12. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
Ishizaki H; Manuel ER; Song GY; Srivastava T; Sun S; Diamond DJ; Ellenhorn JD
Cancer Immunol Immunother; 2011 Jan; 60(1):99-109. PubMed ID: 20960189
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.
Sumida K; Wakita D; Narita Y; Masuko K; Terada S; Watanabe K; Satoh T; Kitamura H; Nishimura T
Eur J Immunol; 2012 Aug; 42(8):2060-72. PubMed ID: 22653638
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.
Mundy-Bosse BL; Lesinski GB; Jaime-Ramirez AC; Benninger K; Khan M; Kuppusamy P; Guenterberg K; Kondadasula SV; Chaudhury AR; La Perle KM; Kreiner M; Young G; Guttridge DC; Carson WE
Cancer Res; 2011 Aug; 71(15):5101-10. PubMed ID: 21680779
[TBL] [Abstract][Full Text] [Related]
15. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
[TBL] [Abstract][Full Text] [Related]
16. IFN-γ regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1.
Medina-Echeverz J; Haile LA; Zhao F; Gamrekelashvili J; Ma C; Métais JY; Dunbar CE; Kapoor V; Manns MP; Korangy F; Greten TF
Eur J Immunol; 2014 Aug; 44(8):2457-67. PubMed ID: 24810636
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models.
Esaki S; Goshima F; Kimura H; Murakami S; Nishiyama Y
Int J Cancer; 2013 Apr; 132(7):1592-601. PubMed ID: 22949155
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.
Hwang KS; Cho WK; Yoo J; Yun HJ; Kim S; Im DS
BMC Cancer; 2005 May; 5():51. PubMed ID: 15910693
[TBL] [Abstract][Full Text] [Related]
19. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak AK; Robinson BW; Lake RA
Cancer Res; 2003 Aug; 63(15):4490-6. PubMed ID: 12907622
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T helper cell-independent antitumor response mediated by murine IFN-beta gene delivery in immunocompetent mice.
Brown JL; Barsoum J; Qin XQ
J Interferon Cytokine Res; 2002 Jun; 22(6):719-28. PubMed ID: 12162884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
